Full-Time

Associate Director/Director

Computational Biologist

Updated on 11/16/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$195k - $285kAnnually

+ Performance Bonus + Equity

Senior

San Francisco, CA, USA

Category
Computational Biology
Genomics
Biology & Biotech
Required Skills
Python
Git
SQL
Postgres
AWS
Data Analysis
Requirements
  • PhD in Bioinformatics, Computational Biology, Functional Genomics or related discipline with 5+ years of industry experience applying multi-omics data analyses in the human context
  • Has direct experience with databases that house multi-omics datasets such as UK Biobank, Human Cell Atlas, Human Protein Atlas, GEO, Expression Atlas, DepMap, etc.
  • Understands the limitations of high-throughput data with direct experience in quality control across multiple types of omics data, as well as how to assess quality of summarized results
  • Expert level of proficiency in quantitative analyses, including mathematics, statistics and computation
  • Able to demonstrate great written and verbal communication skills in conveying analysis results to both experts and non-experts in the field
  • Extensive experience with Python focusing on data analysis and familiarity with git version control; hands on experience in developing data processing pipelines and or developing stand-alone libraries is a plus
  • Understands AWS infrastructure, including EC2, S3 and knowledge of relational databases (SQL, Postgres, etc…); experience in extracting information from such databases
  • Proven track record of peer-reviewed publications in computational biology
Responsibilities
  • Evaluate and contextualize the molecular evidence supporting a genetic disease therapeutic hypothesis with relevant human-derived multi-omics data
  • Guide strategic cross-functional initiatives for exploratory biomarker analysis for target engagement, patient stratification, surrogate endpoints, etc.
  • Design and develop analysis frameworks to utilize data from diverse multiomics sources (ex. Genomics, trancriptomics, epigenomics, proteomics, chemoproteomics, etc.)
  • Interact with both technical and non-technical collaborators, including biologists, physicians, geneticists, and business development & asset acquisition specialists, to evaluate new opportunities and derive analysis-based project decisions
  • Stay current with state-of-the-art methods and most recent data releases, which will require reading academic papers, reproducing algorithms and methods with or without open-source software and ingesting relevant datasets for analyses across various sources

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. The company generates revenue through drug development, licensing agreements, and partnerships, with a diverse pipeline of over 15 drug programs aimed at 20 different genetic diseases. Their culture promotes independent thinking and transparency, enabling quick, data-driven decisions that enhance their drug development process.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

28%

1 year growth

59%

2 year growth

97%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.

Help us improve and share your feedback! Did you find this helpful?